{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:06:00Z","timestamp":1789067160319,"version":"build-2803163510"},"reference-count":130,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Card Fail Rev"],"abstract":"<jats:p>Heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) are subtypes of heart failure with overlapping clinical features but have some distinct functional characteristics and cellular and molecular mechanisms. Exercise training is an accessible, non-pharmacological therapy recommended for the management of HFrEF and is increasingly showing promise for treating HFpEF. This review summarises the underlying pathophysiology of HFrEF and HFpEF and the evidence from clinical and preclinical studies showing that exercise training can improve cardiac function. The authors also summarise the underlying cellular and molecular mechanisms between HFrEF and HFpEF, with respect to cardiac remodelling, fibrosis, mitochondrial adaptations and metabolism, inflammation and inter-organ crosstalk, and provide evidence that exercise training elicits protective adaptations in HFrEF and HFpEF through some different signalling pathways targeted by exercise. Finally, the authors discuss the use of exercise training as a therapeutic intervention for HFrEF and HFpEF through personalised training by phenotype and in combination with emerging pharmacological treatments.<\/jats:p>","DOI":"10.15420\/cfr.2025.62","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:47:28Z","timestamp":1788950848000},"source":"Crossref","is-referenced-by-count":0,"title":["Understanding Exercise-induced Protection in Heart Failure with Reduced Ejection Fraction and Heart Failure with Preserved Ejection Fraction: Molecular Mechanisms and New Therapeutic Opportunities"],"prefix":"10.15420","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5700-1053","authenticated-orcid":false,"given":"Ren Ping","family":"Liu","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046fa4y88","id-type":"ROR","asserted-by":"publisher"}],"name":"The Heart Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8264-0746","authenticated-orcid":false,"given":"Lauren E","family":"Watson","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046fa4y88","id-type":"ROR","asserted-by":"publisher"}],"name":"The Heart Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8316-1066","authenticated-orcid":false,"given":"Julie R","family":"McMullen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046fa4y88","id-type":"ROR","asserted-by":"publisher"}],"name":"The Heart Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 2023;118:3272\u201387. https:\/\/doi.org\/10.1093\/cvr\/cvac013; PMID: 35150240. DOI: 10.1093\/cvr\/cvac013","DOI":"10.1093\/cvr\/cvac013"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Sachdev V, Sharma K, Keteyian SJ, et al. Supervised exercise training for chronic heart failure with preserved ejection fraction: a scientific statement from the American Heart Association and American College of Cardiology. Circulation 2023;147:e699\u2013715. https:\/\/doi.org\/10.1161\/CIR.0000000000001122; PMID: 36943925. DOI: 10.1161\/CIR.0000000000001122","DOI":"10.1161\/CIR.0000000000001122"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Haykowsky M, Brubaker P, Kitzman D. Role of physical training in heart failure with preserved ejection fraction. Curr Heart Fail Rep 2012;9:101\u20136. https:\/\/doi.org\/10.1007\/s11897-012-0087-7; PMID: 22430146. DOI: 10.1007\/s11897-012-0087-7","DOI":"10.1007\/s11897-012-0087-7"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Writing Committee Members. HF STATS 2025: heart failure epidemiology and outcomes statistics \u2013 an updated 2025 report from the Heart Failure Society of America. J Card Fail 2025;32:439\u201398. https:\/\/doi.org\/10.1016\/j.cardfail.2025.07.007; PMID: 40987671. DOI: 10.1016\/j.cardfail.2025.07.007","DOI":"10.1016\/j.cardfail.2025.07.007"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart failure with preserved ejection fraction: JACC scientific statement. J Am Coll Cardiol 2023;81:1810\u201334. https:\/\/doi.org\/10.1016\/j.jacc.2023.01.049; PMID: 37137592. DOI: 10.1016\/j.jacc.2023.01.049","DOI":"10.1016\/j.jacc.2023.01.049"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Bekfani T, Pellicori P, Morris DA, et al. Sarcopenia in patients with heart failure with preserved ejection fraction: impact on muscle strength, exercise capacity and quality of life. Int J Cardiol 2016;222:41\u20136. https:\/\/doi.org\/10.1016\/j.ijcard.2016.07.135; PMID: 27454614. DOI: 10.1016\/j.ijcard.2016.07.135","DOI":"10.1016\/j.ijcard.2016.07.135"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Alcaide P, Kallikourdis M, Emig R, Prabhu SD. Myocardial inflammation in heart failure with reduced and preserved ejection fraction. Circ Res 2024;134:1752\u201366. https:\/\/doi.org\/10.1161\/CIRCRESAHA.124.323659; PMID: 38843295. DOI: 10.1161\/CIRCRESAHA.124.323659","DOI":"10.1161\/CIRCRESAHA.124.323659"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. Circulation 2022;145:e895\u2013e1032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063; PMID: 35363499. DOI: 10.1161\/CIR.0000000000001073","DOI":"10.1161\/CIR.0000000000001073"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Crisci G, De Luca M, D\u2019Assante R, et al. Effects of exercise on heart failure with preserved ejection fraction: an updated review of literature. J Cardiovasc Dev Dis 2022;9:241. https:\/\/doi.org\/10.3390\/jcdd9080241; PMID: 36005405. DOI: 10.3390\/jcdd9080241","DOI":"10.3390\/jcdd9080241"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Odajima S, Tanaka H, Fujimoto W, et al. Efficacy of renin-angiotensin-aldosterone-system inhibitors for heart failure with preserved ejection fraction and left ventricular hypertrophy: from the Kuniumi Registry Acute Cohort. J Cardiol 2022;79:703\u201310. https:\/\/doi.org\/10.1016\/j.jjcc.2021.12.002; PMID: 34924235. DOI: 10.1016\/j.jjcc.2021.12.002","DOI":"10.1016\/j.jjcc.2021.12.002"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Hubers SA, Brown NJ. Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation 2016;133:1115\u201324. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018622; PMID: 26976916. DOI: 10.1161\/CIRCULATIONAHA.115.018622","DOI":"10.1161\/CIRCULATIONAHA.115.018622"},{"key":"ref11","unstructured":"Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381:1609\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1908655; PMID: 31475794."},{"key":"ref12","unstructured":"Mentz RJ, Ward JH, Hernandez AF, et al. Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure. J Am Coll Cardiol 2023;82:1\u201312. https:\/\/doi.org\/10.1016\/j.jacc.2023.04.019; PMID: 37212758."},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Georgianos PI, Kourtidou C, Kontogiorgos I, et al. Mineralocorticoid receptor antagonism with finerenone: a new era in the management of patients with heart failure with mildly reduced or preserved ejection fraction. Am J Cardiovasc Drugs 2025;25:427\u201332. https:\/\/doi.org\/10.1007\/s40256-025-00723-2; PMID: 40055303. DOI: 10.1007\/s40256-025-00723-2","DOI":"10.1007\/s40256-025-00723-2"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Eleyan L, Gonnah AR, Farhad I, et al. Exercise training in heart failure: current evidence and future directions. J Clin Med 2025;14:359. https:\/\/doi.org\/10.3390\/jcm14020359; PMID: 39860365. DOI: 10.3390\/jcm14020359","DOI":"10.3390\/jcm14020359"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Bishop DJ, Lee MJC, Picard M. Exercise as mitochondrial medicine: how does the exercise prescription affect mitochondrial adaptations to training? Annu Rev Physiol 2025;87:107\u201329. https:\/\/doi.org\/10.1146\/annurev-physiol-022724-104836; PMID: 39656953. DOI: 10.1146\/annurev-physiol-022724-104836","DOI":"10.1146\/annurev-physiol-022724-104836"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Poole DC, Richardson RS, Haykowsky MJ, et al. Exercise limitations in heart failure with reduced and preserved ejection fraction. J Appl Physiol (1985) 2018;124:208\u201324. https:\/\/doi.org\/10.1152\/japplphysiol.00747.2017; PMID: 29051336. DOI: 10.1152\/japplphysiol.00747.2017","DOI":"10.1152\/japplphysiol.00747.2017"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Cesari M, Pahor M. Target population for clinical trials on sarcopenia. J Nutr Health Aging 2008;12:470\u20138. https:\/\/doi.org\/10.1007\/bf02982708; PMID: 18615229. DOI: 10.1007\/BF02982708","DOI":"10.1007\/BF02982708"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"F\u00fclster S, Tacke M, Sandek A, et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J 2012;34:512\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehs381; PMID: 23178647. DOI: 10.1093\/eurheartj\/ehs381","DOI":"10.1093\/eurheartj\/ehs381"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Emami A, Saitoh M, Valentova M, et al. Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur J Heart Fail 2018;20:1580\u20137. https:\/\/doi.org\/10.1002\/ejhf.1304; PMID: 30160804. DOI: 10.1002\/ejhf.1304","DOI":"10.1002\/ejhf.1304"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Bauer J, Morley JE, Schols AMWJ, et al. Sarcopenia: a time for action. An SCWD position paper. J Cachexia Sarcopenia Muscle 2019;10:956\u201361. https:\/\/doi.org\/10.1002\/jcsm.12483; PMID: 31523937. DOI: 10.1002\/jcsm.12483","DOI":"10.1002\/jcsm.12483"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Schaap LA, Pluijm SMF, Deeg DJH, Visser M. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med 2006;119:16750969. https:\/\/doi.org\/10.1016\/j.amjmed.2005.10.049; PMID: 16750969. DOI: 10.1016\/j.amjmed.2005.10.049","DOI":"10.1016\/j.amjmed.2005.10.049"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Rolland Y, Czerwinski S, Abellan Van Kan G, et al. Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging 2008;12:433\u201350. https:\/\/doi.org\/10.1007\/bf02982704; PMID: 18615225. DOI: 10.1007\/BF02982704","DOI":"10.1007\/BF02982704"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Pugliese NR, De Biase N, Conte L, et al. Cardiac reserve and exercise capacity: insights from combined cardiopulmonary and exercise echocardiography stress testing. J Am Soc Echocardiogr 2021;34:38\u201350. https:\/\/doi.org\/10.1016\/j.echo.2020.08.015; PMID: 33036818. DOI: 10.1016\/j.echo.2020.08.015","DOI":"10.1016\/j.echo.2020.08.015"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Pugliese NR, Mazzola M, Madonna R, et al. Exercise-induced pulmonary hypertension in HFpEF and HFrEF: different pathophysiologic mechanism behind similar functional impairment. Vascul Pharmacol 2022;144:106978. https:\/\/doi.org\/10.1016\/j.vph.2022.106978; PMID: 35301117. DOI: 10.1016\/j.vph.2022.106978","DOI":"10.1016\/j.vph.2022.106978"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Pugliese NR, Mazzola M, Fabiani I, et al. Haemodynamic and metabolic phenotyping of hypertensive patients with and without heart failure by combining cardiopulmonary and echocardiographic stress test. Eur J Heart Fail 2020;22:458\u201368. https:\/\/doi.org\/10.1002\/ejhf.1739; PMID: 31950651. DOI: 10.1002\/ejhf.1739","DOI":"10.1002\/ejhf.1739"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Pugliese NR, Fabiani I, Santini C, et al. Value of combined cardiopulmonary and echocardiography stress test to characterize the haemodynamic and metabolic responses of patients with heart failure and mid-range ejection fraction. Eur Heart J Cardiovasc Imaging 2019;20:828\u201336. https:\/\/doi.org\/10.1093\/ehjci\/jez014; PMID: 30753369. DOI: 10.1093\/ehjci\/jez014","DOI":"10.1093\/ehjci\/jez014"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Lu X, Chen Y, Shi Y, et al. Exercise and exerkines: mechanisms and roles in anti-aging and disease prevention. Exp Gerontol 2025;200:112685. https:\/\/doi.org\/10.1016\/j.exger.2025.112685; PMID: 39818278. DOI: 10.1016\/j.exger.2025.112685","DOI":"10.1016\/j.exger.2025.112685"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"La Gerche A, Howden EJ, Haykowsky MJ, et al. Heart failure with preserved ejection fraction as an exercise deficiency syndrome: JACC focus seminar 2\/4. J Am Coll Cardiol 2022;80:1177\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2022.07.011; PMID: 36075837. DOI: 10.1016\/j.jacc.2022.07.011","DOI":"10.1016\/j.jacc.2022.07.011"},{"key":"ref29","unstructured":"Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129\u2013200. https:\/\/doi.org\/10.1093\/eurheartj\/ehw128; PMID: 27206819."},{"key":"ref30","unstructured":"O\u2019Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009;301:1439\u201350. https:\/\/doi.org\/10.1001\/jama.2009.454; PMID: 19351941."},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Molloy CD, Long L, Mordi IR, et al. Exercise-based cardiac rehabilitation for adults with heart failure: 2023 Cochrane systematic review and meta-analysis. Eur J Heart Fail 2023;25:2263\u201373. https:\/\/doi.org\/10.1002\/ejhf.3046; PMID: 37850321. DOI: 10.1002\/ejhf.3046","DOI":"10.1002\/ejhf.3046"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Laoutaris ID, Piotrowicz E, Kallistratos MS, et al. Combined aerobic\/resistance\/inspiratory muscle training as the \u201coptimum\u201d exercise programme for patients with chronic heart failure: ARISTOS-HF randomized clinical trial. Eur J Prev Cardiol 2021;28:1626\u201335. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa091; PMID: 33624071. DOI: 10.1093\/eurjpc\/zwaa091","DOI":"10.1093\/eurjpc\/zwaa091"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Zhang CY, Li KL, Zhao XX, et al. The role and underlying mechanisms of exercise in heart failure. Rev Cardiovasc Med 2024;25:285. https:\/\/doi.org\/10.31083\/j.rcm2508285; PMID: 39228484. DOI: 10.31083\/j.rcm2508285","DOI":"10.31083\/j.rcm2508285"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Hsu CC, Fu TC, Wang CH, et al. High-intensity interval training is associated with improved 10-year survival by mediating left ventricular remodeling in patients with heart failure with reduced and mid-range ejection fraction. J Am Heart Assoc 2024;13:e031162. https:\/\/doi.org\/10.1161\/JAHA.123.031162; PMID: 38240219. DOI: 10.1161\/JAHA.123.031162","DOI":"10.1161\/JAHA.123.031162"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Kitzman DW, Brubaker PH, Morgan TM, et al. Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Circ Heart Fail 2010;3:659\u201367. https:\/\/doi.org\/10.1161\/circheartfailure.110.958785; PMID: 20852060. DOI: 10.1161\/CIRCHEARTFAILURE.110.958785","DOI":"10.1161\/CIRCHEARTFAILURE.110.958785"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Edelmann F, Gelbrich G, D\u00fcngen HD, et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise Training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol 2011;58:1780\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2011.06.054; PMID: 21996391. DOI: 10.1016\/j.jacc.2011.06.054","DOI":"10.1016\/j.jacc.2011.06.054"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Donelli da Silveira A, Beust de Lima J, da Silva Piardi D, et al. High-intensity interval training is effective and superior to moderate continuous training in patients with heart failure with preserved ejection fraction: a randomized clinical trial. Eur J Prev Cardiol 2020;27:1733\u201343. https:\/\/doi.org\/10.1177\/2047487319901206; PMID: 31964186. DOI: 10.1177\/2047487319901206","DOI":"10.1177\/2047487319901206"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Leggio M, Fusco A, Loreti C, et al. Effects of exercise training in heart failure with preserved ejection fraction: an updated systematic literature review. Heart Fail Rev 2020;25:703\u201311. https:\/\/doi.org\/10.1007\/s10741-019-09841-x; PMID: 31399956. DOI: 10.1007\/s10741-019-09841-x","DOI":"10.1007\/s10741-019-09841-x"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Tarnavski O, McMullen JR, Schinke M, et al. Mouse cardiac surgery: comprehensive techniques for the generation of mouse models of human diseases and their application for genomic studies; Physiol Genomics 2004;16:349\u201360. https:\/\/doi.org\/10.1152\/physiolgenomics.00041.2003; PMID: 14679301. DOI: 10.1152\/physiolgenomics.00041.2003","DOI":"10.1152\/physiolgenomics.00041.2003"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Liu S, Meng X, Li G, et al. Exercise training after myocardial infarction attenuates dysfunctional ventricular remodeling and promotes cardiac recovery. Rev Cardiovasc Med 2022;23:148. https:\/\/doi.org\/10.31083\/j.rcm2304148; PMID: 39076229. DOI: 10.31083\/j.rcm2304148","DOI":"10.31083\/j.rcm2304148"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Wisl\u00f8ff U, Loennechen JP, Currie S, et al. Aerobic exercise reduces cardiomyocyte hypertrophy and increases contractility, Ca2+ sensitivity and SERCA-2 in rat after myocardial infarction. Cardiovasc Res 2002;54:162\u201374. https:\/\/doi.org\/10.1016\/S0008-6363(01)00565-X; PMID: 12062372. DOI: 10.1016\/S0008-6363(01)00565-X","DOI":"10.1016\/S0008-6363(01)00565-X"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Calvert JW, Condit ME, Arag\u00f3n JP, et al. Exercise protects against myocardial ischemia-reperfusion injury via stimulation of \u0392(3)-adrenergic receptors and increased nitric oxide signaling: role of nitrite and nitrosothiols. Circ Res 2011;108:1448\u201358. https:\/\/doi.org\/10.1161\/circresaha.111.241117; PMID: 21527738. DOI: 10.1161\/CIRCRESAHA.111.241117","DOI":"10.1161\/CIRCRESAHA.111.241117"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Nicholson CK, Lambert JP, Chow CW, et al. Chronic exercise downregulates myocardial myoglobin and attenuates nitrite reductase capacity during ischemia\u2013reperfusion. J Mol Cell Cardiol 2013;64:1\u201310. https:\/\/doi.org\/10.1016\/j.yjmcc.2013.08.002; PMID: 23962643. DOI: 10.1016\/j.yjmcc.2013.08.002","DOI":"10.1016\/j.yjmcc.2013.08.002"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"B\u00f6ttner J, Werner S, Adams V, et al. Structural and functional alterations in heart and skeletal muscle following severe TAC in mice: impact of moderate exercise training. Biol Res 2021;54:31. https:\/\/doi.org\/10.1186\/s40659-021-00354-2; PMID: 34538250. DOI: 10.1186\/s40659-021-00354-2","DOI":"10.1186\/s40659-021-00354-2"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Ni L, Lu B, Peng G, et al. Exercise-preconditioning attenuates TAC-induced cardiac hypertrophy and myocardial injury through activating NRF2. Free Radic Biol Med 2025;239:80\u201390. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2025.07.024; PMID: 40681061. DOI: 10.1016\/j.freeradbiomed.2025.07.024","DOI":"10.1016\/j.freeradbiomed.2025.07.024"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Weeks KL, Gao X, Du X-J, et al; Phosphoinositide 3-kinase P110\u03b1 is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction. Circ Heart Fail 2012;5:523\u201334. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.112.966622; PMID: 22705768. DOI: 10.1161\/CIRCHEARTFAILURE.112.966622","DOI":"10.1161\/CIRCHEARTFAILURE.112.966622"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Buerger A, Rozhitskaya O, Sherwood MC, et al. Dilated cardiomyopathy resulting from high-level myocardial expression of Cre-recombinase. J Card Fail 2006;12:392\u20138. https:\/\/doi.org\/10.1016\/j.cardfail.2006.03.002; PMID: 16762803. DOI: 10.1016\/j.cardfail.2006.03.002","DOI":"10.1016\/j.cardfail.2006.03.002"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"McMullen JR, Amirahmadi F, Woodcock EA, et al; Protective effects of exercise and phosphoinositide 3-kinase(P110alpha) signaling in dilated and hypertrophic cardiomyopathy; Proc Natl Acad Sci USA 2007;104:612\u20137. https:\/\/doi.org\/10.1073\/pnas.0606663104; PMID: 17202264. DOI: 10.1073\/pnas.0606663104","DOI":"10.1073\/pnas.0606663104"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Gao Z, Novick M, Muller MD, et al. Exercise and diet-induced weight loss attenuates oxidative stress related-coronary vasoconstriction in obese adolescents. Eur J Appl Physiol 2013;113:519\u201328. https:\/\/doi.org\/10.1007\/s00421-012-2459-9; PMID: 22814577. DOI: 10.1007\/s00421-012-2459-9","DOI":"10.1007\/s00421-012-2459-9"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Mishra S, Kass DA. Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 2021;18:400\u201323. https:\/\/doi.org\/10.1038\/s41569-020-00480-6; PMID: 33432192. DOI: 10.1038\/s41569-020-00480-6","DOI":"10.1038\/s41569-020-00480-6"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Schiattarella GG, Altamirano F, Tong D, et al. Nitrosative stress drives heart failure with preserved ejection fraction. Nature 2019;568:351\u20136. https:\/\/doi.org\/10.1038\/s41586-019-1100-z; PMID: 30971818. DOI: 10.1038\/s41586-019-1100-z","DOI":"10.1038\/s41586-019-1100-z"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Liu K, Ju W, Ouyang S, et al. Exercise training ameliorates myocardial phenotypes in heart failure with preserved ejection fraction by changing N6-methyladenosine modification in mice model. Front Cell Dev Biol 2022;10:954769. https:\/\/doi.org\/10.3389\/fcell.2022.954769; PMID: 36120562. DOI: 10.3389\/fcell.2022.954769","DOI":"10.3389\/fcell.2022.954769"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Quiriarte H, Noland RC, Stampley JE, et al. Exercise therapy rescues skeletal muscle dysfunction and exercise intolerance in cardiometabolic HFpEF. JACC Basic Transl Sci 2024;9:1409\u201325. https:\/\/doi.org\/10.1016\/j.jacbts.2024.07.009; PMID: 39822600. DOI: 10.1016\/j.jacbts.2024.07.009","DOI":"10.1016\/j.jacbts.2024.07.009"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Nguyen ITN, Brandt MM, van de Wouw J, et al. Both male and female obese ZSF1 rats develop cardiac dysfunction in obesity-induced heart failure with preserved ejection fraction; PLoS One 2020;15:e0232399. https:\/\/doi.org\/10.1371\/journal.pone.0232399; PMID: 32374790. DOI: 10.1371\/journal.pone.0232399","DOI":"10.1371\/journal.pone.0232399"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Schauer A, Draskowski R, Jannasch A, et al. ZSF1 rat as animal model for HFpEF: development of reduced diastolic function and skeletal muscle dysfunction. ESC Heart Fail 2020;7:2123\u201334. https:\/\/doi.org\/10.1002\/ehf2.12915; PMID: 32710530. DOI: 10.1002\/ehf2.12915","DOI":"10.1002\/ehf2.12915"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Bowen TS, Brauer D, Rolim NPL, et al. Exercise training reveals inflexibility of the diaphragm in an animal model of patients with obesity\u2010driven heart failure with a preserved ejection fraction. J Am Heart Assoc 2017;6:e006416. https:\/\/doi.org\/10.1161\/JAHA.117.006416; PMID: 29066440. DOI: 10.1161\/JAHA.117.006416","DOI":"10.1161\/JAHA.117.006416"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Oliveira MI, Leite S, Barros A, et al. Histological and haemodynamic characterization of right ventricle in sedentary and trained rats with heart failure with preserved ejection fraction. Exp Physiol 2021;106:2457\u201371. https:\/\/doi.org\/10.1113\/EP089516; PMID: 34676608. DOI: 10.1113\/EP089516","DOI":"10.1113\/EP089516"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Simmonds SJ, Cuijpers I, Heymans S, Jones EAV. Cellular and molecular differences between HFpEF and HFrEF: a step ahead in an improved pathological understanding. Cells 2020;9:242. https:\/\/doi.org\/10.3390\/cells9010242; PMID: 31963679. DOI: 10.3390\/cells9010242","DOI":"10.3390\/cells9010242"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Shimizu I, Minamino T; Physiological and pathological cardiac hypertrophy. J Mol Cell Cardiol 2016;97:245\u201362. https:\/\/doi.org\/10.1016\/j.yjmcc.2016.06.001; PMID: 27262674. DOI: 10.1016\/j.yjmcc.2016.06.001","DOI":"10.1016\/j.yjmcc.2016.06.001"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"van Heerebeek L, Borb\u00e9ly A, Niessen HWM, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006;113:1966\u201373. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.587519; PMID: 16618817. DOI: 10.1161\/CIRCULATIONAHA.105.587519","DOI":"10.1161\/CIRCULATIONAHA.105.587519"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Pretorius L, Du XJ, Woodcock EA, et al. Reduced phosphoinositide 3-kinase (P110alpha) activation increases the susceptibility to atrial fibrillation. Am J Pathol 2009;175:998\u20131009. https:\/\/doi.org\/10.2353\/ajpath.2009.090126; PMID: 19679877. DOI: 10.1016\/j.hlc.2009.05.299","DOI":"10.1016\/j.hlc.2009.05.299"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Bass-Stringer S, Bernardo BC, Yildiz GS, et al. Reduced PI3K(P110\u03b1) induces atrial myopathy, and PI3K-related lipids are dysregulated in athletes with atrial fibrillation. J Sport Health Sci 2025;14:101023. https:\/\/doi.org\/10.1016\/j.jshs.2025.101023; PMID: 39826614. DOI: 10.1016\/j.jshs.2025.101023","DOI":"10.1016\/j.jshs.2025.101023"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Lin RCY, Weeks KL, Gao X-M, et al; PI3K(P110\u03b1) protects against myocardial infarction-induced heart failure. Arterioscler Thromb Vasc Biol 2010;30:724\u201332. https:\/\/doi.org\/10.1161\/ATVBAHA.109.201988; PMID: 20237330. DOI: 10.1161\/ATVBAHA.109.201988","DOI":"10.1161\/ATVBAHA.109.201988"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Bernardo BC, Gao XM, Winbanks CE, et al. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function; Proc Natl Acad Sci U S A 2012;109:17615\u201320. https:\/\/doi.org\/10.1073\/pnas.1206432109; PMID: 23047694. DOI: 10.1073\/pnas.1206432109","DOI":"10.1073\/pnas.1206432109"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Bernardo BC, Gao XM, Tham YK, et al. Silencing of miR-34a attenuates cardiac dysfunction in a setting of moderate, but not severe, hypertrophic cardiomyopathy; PLoS One 2014;9:e90337. https:\/\/doi.org\/10.1371\/journal.pone.0090337; PMID: 24587330. DOI: 10.1371\/journal.pone.0090337","DOI":"10.1371\/journal.pone.0090337"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Bernardo BC, Nguyen SS, Gao X-M, et al. Inhibition of miR-154 protects against cardiac dysfunction and fibrosis in a mouse model of pressure overload. Sci Rep 2016;6:22442. https:\/\/doi.org\/10.1038\/srep22442; PMID: 26928825. DOI: 10.1038\/srep22442","DOI":"10.1038\/srep22442"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Bernardo BC, Nguyen SS, Winbanks CE, et al. Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy. FASEB J 2014;28:5097\u2013110. https:\/\/doi.org\/10.1096\/fj.14-253856; PMID: 25145628. DOI: 10.1096\/fj.14-253856","DOI":"10.1096\/fj.14-253856"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Bass-Stringer S, Donner DG, May CN, et al. Generation and evaluation of a novel PI3K-targeting gene therapy in the failing mouse heart and healthy sheep heart. J Mol Cell Cardiol Plus 2025;13:100478. https:\/\/doi.org\/10.1016\/j.jmccpl.2025.100478; PMID: 40809785. DOI: 10.1016\/j.jmccpl.2025.100478","DOI":"10.1016\/j.jmccpl.2025.100478"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Chen YC, Zheng G, Donner DG, et al. Cardiovascular magnetic resonance imaging for sequential assessment of cardiac fibrosis in mice: technical advancements and reverse translation. Am J Physiol Heart Circ Physiol 2023;326:H1\u201324. https:\/\/doi.org\/10.1152\/ajpheart.00437.2023; PMID: 37921664. DOI: 10.1152\/ajpheart.00437.2023","DOI":"10.1152\/ajpheart.00437.2023"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Zhao Z, Cui X, Liao Z. Mechanism of fibroblast growth factor 21 in cardiac remodeling. Front Cardiovasc Med 2023;10:1202730. https:\/\/doi.org\/10.3389\/fcvm.2023.1202730; PMID: 37416922. DOI: 10.3389\/fcvm.2023.1202730","DOI":"10.3389\/fcvm.2023.1202730"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Ma Y, Kuang Y, Bo W, et al. Exercise training alleviates cardiac fibrosis through increasing fibroblast growth factor 21 and regulating TGF-\u03921-Smad2\/3-MMP2\/9 signaling in mice with myocardial infarction. Int J Mol Sci 2021;22:12341. https:\/\/doi.org\/10.3390\/ijms222212341; PMID: 34830222. DOI: 10.3390\/ijms222212341","DOI":"10.3390\/ijms222212341"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Bo W, Ma Y, Feng L, et al. FGF21 promotes myocardial angiogenesis and mediates the cardioprotective effects of exercise in myocardial infarction mice. J Appl Physiol (1985) 2023;135:696\u2013705. https:\/\/doi.org\/10.1152\/japplphysiol.00307.2023; PMID: 37535710. DOI: 10.1152\/japplphysiol.00307.2023","DOI":"10.1152\/japplphysiol.00307.2023"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Fu G, Wang Z, Hu S. Exercise improves cardiac fibrosis by stimulating the release of endothelial progenitor cell-derived exosomes and upregulating miR-126 expression. Front Cardiovasc Med 2024;11:1323329. https:\/\/doi.org\/10.3389\/fcvm.2024.1323329; PMID: 38798919. DOI: 10.3389\/fcvm.2024.1323329","DOI":"10.3389\/fcvm.2024.1323329"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Ren W, Xi Y, Ma Y, et al. Aerobic exercise upregulates renal-derived ELABELA to improve myocardial fibrosis by activating APJ-AMPK-Sirt1 and inhibiting TGF\u03b21-Smad2\/3 signaling pathways in myocardial infarction mice. FASEB J 2025;39:e70734. https:\/\/doi.org\/10.1096\/fj.202402897RR; PMID: 40540261. DOI: 10.1096\/fj.202402897RR","DOI":"10.1096\/fj.202402897RR"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Malik MK, Kinno M, Liebo M, et al. Evolving role of myocardial fibrosis in heart failure with preserved ejection fraction. Front Cardiovasc Med 2025;12:1573346. https:\/\/doi.org\/10.3389\/fcvm.2025.1573346; PMID: 40336640. DOI: 10.3389\/fcvm.2025.1573346","DOI":"10.3389\/fcvm.2025.1573346"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Zhang K, Gan J, Wang B, et al. FGF21 protects against HFpEF by improving cardiac mitochondrial bioenergetics in mice. Nat Commun 2025;16:1661. https:\/\/doi.org\/10.1038\/s41467-025-56885-9; PMID: 39955281. DOI: 10.1038\/s41467-025-56885-9","DOI":"10.1038\/s41467-025-56885-9"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Hong Y, Yang AL, Wong JKS, et al. Exercise intervention prevents early aged hypertension-caused cardiac dysfunction through inhibition of cardiac fibrosis. Aging (Albany, NY) 2022;14:4390\u2013401. https:\/\/doi.org\/10.18632\/aging.204077; PMID: 35604403. DOI: 10.18632\/aging.204077","DOI":"10.18632\/aging.204077"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Jin D, Yang XY, Wang JS. MicroRNA-126 level increases during exercise rehabilitation of heart failure with a preserved ejection fraction. Int J Gen Med 2021;14:3397\u2013404. https:\/\/doi.org\/10.2147\/ijgm.S316285; PMID: 34285564. DOI: 10.2147\/IJGM.S316285","DOI":"10.2147\/IJGM.S316285"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Liu Z, Gao L, Cheng L, et al. The roles of N6-methyladenosine and its target regulatory noncoding RNAS in tumors: classification, mechanisms, and potential therapeutic implications. Exp Mol Med 2023;55:487\u2013501. https:\/\/doi.org\/10.1038\/s12276-023-00944-y; PMID: 36854773. DOI: 10.1038\/s12276-023-00944-y","DOI":"10.1038\/s12276-023-00944-y"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Zhang B, Xu Y, Cui X, et al. Alteration of m6A RNA methylation in heart failure with preserved ejection fraction. Front Cardiovasc Med 2021;8:647806. https:\/\/doi.org\/10.3389\/fcvm.2021.647806; PMID: 33748197. DOI: 10.3389\/fcvm.2021.647806","DOI":"10.3389\/fcvm.2021.647806"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Chaanine AH, Joyce LD, Stulak JM, et al. Mitochondrial morphology, dynamics, and function in human pressure overload or ischemic heart disease with preserved or reduced ejection fraction. Circ Heart Fail 2019;12:e005131. https:\/\/doi.org\/10.1161\/circheartfailure.118.005131; PMID: 30744415. DOI: 10.1161\/CIRCHEARTFAILURE.118.005131","DOI":"10.1161\/CIRCHEARTFAILURE.118.005131"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Martinez CS, Zheng A, Xiao Q. Mitochondrial reactive oxygen species dysregulation in heart failure with preserved ejection fraction: a fraction of the whole. Antioxidants (Basel) 2024;13:1330. https:\/\/doi.org\/10.3390\/antiox13111330; PMID: 39594472. DOI: 10.3390\/antiox13111330","DOI":"10.3390\/antiox13111330"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Shehadeh LA, Robleto E, Lopaschuk GD. Cardiac energy substrate utilization in heart failure with preserved ejection fraction: reconciling conflicting evidence on fatty acid and glucose metabolism. Am J Physiol Heart Circ Physiol 2025;328:H1267\u201395. https:\/\/doi.org\/10.1152\/ajpheart.00121.2025; PMID: 40251758. DOI: 10.1152\/ajpheart.00121.2025","DOI":"10.1152\/ajpheart.00121.2025"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Mengozzi A, Armenia S, De Biase N, et al. Circulating mitochondrial DNA signature in cardiometabolic patients. Cardiovasc Diabetol 2025;24:106. https:\/\/doi.org\/10.1186\/s12933-025-02656-1; PMID: 40045401. DOI: 10.1186\/s12933-025-02656-1","DOI":"10.1186\/s12933-025-02656-1"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Shen Q, Wu X, Huang C, et al. Aerobic exercise activates AMPK\/PGC-1\u03b1 pathway, inhibits cardiomyocyte apoptosis improves mitochondrial and infarcted heart function. Dokl Biochem Biophys 2024;518:420\u20138. https:\/\/doi.org\/10.1134\/S1607672924600556; PMID: 39196531. DOI: 10.1134\/S1607672924600556","DOI":"10.1134\/S1607672924600556"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Veeranki S, Givvimani S, Kundu S, et al. Moderate intensity exercise prevents diabetic cardiomyopathy associated contractile dysfunction through restoration of mitochondrial function and connexin 43 levels in db\/db mice. J Mol Cell Cardiol 2016;92:163\u201373. https:\/\/doi.org\/10.1016\/j.yjmcc.2016.01.023; PMID: 26827898. DOI: 10.1016\/j.yjmcc.2016.01.023","DOI":"10.1016\/j.yjmcc.2016.01.023"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Zhang H, Zhang Y, Zhang J, Jia D. Exercise alleviates cardiovascular diseases by improving mitochondrial homeostasis. J Am Heart Assoc 2024;13:e036555. https:\/\/doi.org\/10.1161\/JAHA.124.036555; PMID: 39291488. DOI: 10.1161\/JAHA.124.036555","DOI":"10.1161\/JAHA.124.036555"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Cui X, Spanos M, Zhao C, et al. Mitochondrial dysfunction in HFpEF: potential interventions through exercise. J Cardiovasc Transl Res 2025;18:442\u201356. https:\/\/doi.org\/10.1007\/s12265-025-10591-5; PMID: 39863753. DOI: 10.1007\/s12265-025-10591-5","DOI":"10.1007\/s12265-025-10591-5"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"De Biase N, Del Punta L, L\u2019Hoyes W, et al. Associations of iron deficiency with cardiac function, congestion, exercise capacity and prognosis in heart failure. Eur J Heart Fail 2025;27:889\u2013900. https:\/\/doi.org\/10.1002\/ejhf.3534; PMID: 39607281. DOI: 10.1002\/ejhf.3534","DOI":"10.1002\/ejhf.3534"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Jaconiano E, Moreira-Gon\u00e7alves D. Unveiling the role of exercise training in targeting the inflammatory paradigm of heart failure with preserved ejection fraction: a narrative review. Heart Fail Rev 2022;27:163\u201390. https:\/\/doi.org\/10.1007\/s10741-021-10138-1; PMID: 34244870. DOI: 10.1007\/s10741-021-10138-1","DOI":"10.1007\/s10741-021-10138-1"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Pearson MJ, Mungovan SF, Smart NA. Effect of aerobic and resistance training on inflammatory markers in heart failure patients: systematic review and meta-analysis. Heart Fail Rev 2018;23:209\u201323. https:\/\/doi.org\/10.1007\/s10741-018-9677-0; PMID: 29392623. DOI: 10.1007\/s10741-018-9677-0","DOI":"10.1007\/s10741-018-9677-0"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Wei W, Xie P, Wang X. Interval training suppresses nod-like receptor protein 3 inflammasome activation to improve cardiac function in myocardial infarction rats by hindering the activation of the transforming growth factor-\u03921 pathway. J Cardiothorac Surg 2024;19:283. https:\/\/doi.org\/10.1186\/s13019-024-02756-1; PMID: 38730417. DOI: 10.1186\/s13019-024-02756-1","DOI":"10.1186\/s13019-024-02756-1"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Zhang M, Alemasi A, Zhao M, et al. Exercise training attenuates acute \u0392-adrenergic receptor activation-induced cardiac inflammation via the activation of AMP-activated protein kinase. Int J Mol Sci 2023;24:9263. https:\/\/doi.org\/10.3390\/ijms24119263; PMID: 37298222. DOI: 10.3390\/ijms24119263","DOI":"10.3390\/ijms24119263"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Ciccarelli M, Dawson D, Falcao-Pires I, et al. Reciprocal organ interactions during heart failure: a position paper from the ESC Working Group on Myocardial Function. Cardiovasc Res 2021;117:2416\u201333. https:\/\/doi.org\/10.1093\/cvr\/cvab009; PMID: 33483724. DOI: 10.1093\/cvr\/cvab009","DOI":"10.1093\/cvr\/cvab009"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Saw EL, Ramachandran S, Valero-Mu\u00f1oz M, Sam F. Skeletal muscle (dys)function in heart failure with preserved ejection fraction. Curr Opin Cardiol 2021;36:219\u201326. https:\/\/doi.org\/10.1097\/hco.0000000000000824; PMID: 33394707. DOI: 10.1097\/HCO.0000000000000824","DOI":"10.1097\/HCO.0000000000000824"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"Sen MG, Chooi R, McMullen JR. Heart-derived factors and organ cross-talk in settings of health and disease: new knowledge and clinical opportunities for multimorbidity. J Physiol 2025. https:\/\/doi.org\/10.1113\/JP287400; PMID: 39888058; epub ahead of press. DOI: 10.1113\/JP287400","DOI":"10.1113\/JP287400"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"Pugliese NR, Paneni F, Mazzola M, et al. Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure. Eur J Heart Fail 2021;23:1858\u201371. https:\/\/doi.org\/10.1002\/ejhf.2337; PMID: 34427016. DOI: 10.1002\/ejhf.2337","DOI":"10.1002\/ejhf.2337"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"Epelde F. Optimizing cardiac rehabilitation in heart failure: comprehensive insights, barriers, and future strategies. Medicina (Kaunas) 2024;60:1583. https:\/\/doi.org\/10.3390\/medicina60101583; PMID: 39459370. DOI: 10.3390\/medicina60101583","DOI":"10.3390\/medicina60101583"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"Karisa P, Sylviana N, Fitria N, Setiawan S. FSTL-1 as a novel cardiokine of cardiac angiogenesis: a systematic review. Vasc Health Risk Manag 2025;21:437\u201349. https:\/\/doi.org\/10.2147\/vhrm.S509482; PMID: 40453420. DOI: 10.2147\/VHRM.S509482","DOI":"10.2147\/VHRM.S509482"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"Winzer EB, Augstein A, Schauer A, et al. Impact of different training modalities on molecular alterations in skeletal muscle of patients with heart failure with preserved ejection fraction: a substudy of the OptimEx trial. Circ Heart Fail 2022;15:e009124. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.121.009124; PMID: 36200450. DOI: 10.1161\/CIRCHEARTFAILURE.121.009124","DOI":"10.1161\/CIRCHEARTFAILURE.121.009124"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"Vargas-Ortiz K, P\u00e9rez-V\u00e1zquez V, Mac\u00edas-Cervantes MH. Exercise and sirtuins: a way to mitochondrial health in skeletal muscle. Int J Mol Sci 2019;20:2717. https:\/\/doi.org\/10.3390\/ijms20112717; PMID: 31163574. DOI: 10.3390\/ijms20112717","DOI":"10.3390\/ijms20112717"},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"Pugliese NR, Balletti A, Armenia S, et al. Ventricular-arterial coupling derived from proximal aortic stiffness and aerobic capacity across the heart failure spectrum. JACC Cardiovasc Imaging 2022;15:1545\u201359. https:\/\/doi.org\/10.1016\/j.jcmg.2022.03.024; PMID: 36075614. DOI: 10.1016\/j.jcmg.2022.03.024","DOI":"10.1016\/j.jcmg.2022.03.024"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"Dinges SM-T, Schwedhelm E, Schoenfeld J, et al. Effects of exercise training on nitric oxide metabolites in heart failure with reduced or preserved ejection fraction: a secondary analysis of the SMARTEX-HF and OptimEx-Clin trials. Eur J Prev Cardiol 2025;32:949\u201360. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf142; PMID: 40083304. DOI: 10.1093\/eurjpc\/zwaf142","DOI":"10.1093\/eurjpc\/zwaf142"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"Mounsey LA, Guo M, Lau ES, Ho JE. Exercise training in heart failure: clinical benefits and mechanisms. Circ Res 2025;137:273\u201389. https:\/\/doi.org\/10.1161\/CIRCRESAHA.124.325533; PMID: 40608852. DOI: 10.1161\/CIRCRESAHA.124.325533","DOI":"10.1161\/CIRCRESAHA.124.325533"},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"Blackwell JA, Stanford KI. Exercise-induced intertissue communication: adipose tissue and the heart. Curr Opin Physiol 2023;31:100626. https:\/\/doi.org\/10.1016\/j.cophys.2022.100626; PMID: 36588657. DOI: 10.1016\/j.cophys.2022.100626","DOI":"10.1016\/j.cophys.2022.100626"},{"key":"ref106","doi-asserted-by":"crossref","unstructured":"Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol 2018;15:505\u201322. https:\/\/doi.org\/10.1038\/s41569-018-0064-2; PMID: 30065258. DOI: 10.1038\/s41569-018-0064-2","DOI":"10.1038\/s41569-018-0064-2"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"Sorimachi H, Omote K, Omar M, et al. Sex and central obesity in heart failure with preserved ejection fraction. Eur J Heart Fail 2022;24:1359\u201370. https:\/\/doi.org\/10.1002\/ejhf.2563; PMID: 35599453. DOI: 10.1002\/ejhf.2563","DOI":"10.1002\/ejhf.2563"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"Tham YK, Bernardo BC, Claridge B, et al. Estrogen receptor alpha deficiency in cardiomyocytes reprograms the heart-derived extracellular vesicle proteome and induces obesity in female mice. Nat Cardiovasc Res 2023;2:268\u201389. https:\/\/doi.org\/10.1038\/s44161-023-00223-z; PMID: 39196021. DOI: 10.1038\/s44161-023-00223-z","DOI":"10.1038\/s44161-023-00223-z"},{"key":"ref109","doi-asserted-by":"crossref","unstructured":"Ribas V, Drew BG, Zhou Z, et al. Skeletal muscle action of estrogen receptor \u03b1 is critical for the maintenance of mitochondrial function and metabolic homeostasis in females. Sci Transl Med 2016;8:334ra54. https:\/\/doi.org\/10.1126\/scitranslmed.aad3815; PMID: 27075628. DOI: 10.1126\/scitranslmed.aad3815","DOI":"10.1126\/scitranslmed.aad3815"},{"key":"ref110","doi-asserted-by":"crossref","unstructured":"Tong D, Schiattarella GG, Jiang N, et al. Female sex is protective in a preclinical model of heart failure with preserved ejection fraction. Circulation 2019;140:1769\u201371. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.042267; PMID: 31738599. DOI: 10.1161\/CIRCULATIONAHA.119.042267","DOI":"10.1161\/CIRCULATIONAHA.119.042267"},{"key":"ref111","doi-asserted-by":"crossref","unstructured":"Methawasin M, Strom J, Marino VA, et al. An ovary-intact postmenopausal HFpEF mouse model; menopause is more than just estrogen deficiency. Am J Physiol Heart Circ Physiol 2025;328:H719\u201333. https:\/\/doi.org\/10.1152\/ajpheart.00575.2024; PMID: 39963865. DOI: 10.1152\/ajpheart.00575.2024","DOI":"10.1152\/ajpheart.00575.2024"},{"key":"ref112","doi-asserted-by":"crossref","unstructured":"McDonough DJ. Resistance exercise in treating heart failure with preserved ejection fraction (HFpEF) and obesity: targeting skeletal muscle abnormalities and ectopic adipose depots; Physiologia 2025;5:10. https:\/\/doi.org\/10.3390\/physiologia5010010; PMID: 40881192. DOI: 10.3390\/physiologia5010010","DOI":"10.3390\/physiologia5010010"},{"key":"ref113","doi-asserted-by":"crossref","unstructured":"Voorrips SN, Saucedo-Orozco H, S\u00e1nchez-Aguilera PI, et al. Could SGLT2 inhibitors improve exercise intolerance in chronic heart failure? Int J Mol Sci 2022;23:8631. https:\/\/doi.org\/10.3390\/ijms23158631; PMID: 35955784. DOI: 10.3390\/ijms23158631","DOI":"10.3390\/ijms23158631"},{"key":"ref114","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368; PMID: 34447992."},{"key":"ref115","doi-asserted-by":"crossref","unstructured":"Jaiswal A, Jaiswal V, Ang SP, et al. SGLT2 inhibitors among patients with heart failure with preserved ejection fraction: a meta-analysis of randomised controlled trials. Medicine (Baltimore) 2023;102:e34693. https:\/\/doi.org\/10.1097\/md.0000000000034693; PMID: 37773799. DOI: 10.1097\/MD.0000000000034693","DOI":"10.1097\/MD.0000000000034693"},{"key":"ref116","doi-asserted-by":"crossref","unstructured":"Berger JH, Shi Y, Matsuura TR, et al. Two-hit mouse model of heart failure with preserved ejection fraction combining diet-induced obesity and renin-mediated hypertension. Sci Rep 2025;15:422. https:\/\/doi.org\/10.1038\/s41598-024-84515-9; PMID: 39747575. DOI: 10.1038\/s41598-024-84515-9","DOI":"10.1038\/s41598-024-84515-9"},{"key":"ref117","doi-asserted-by":"crossref","unstructured":"Cinti F, Laborante R, Cappannoli L, et al. The effects of SGLT2i on cardiac metabolism in patients with HFpEF: fact or fiction? Cardiovasc Diabetol 2025;24:208. https:\/\/doi.org\/10.1186\/s12933-025-02767-9; PMID: 40369599. DOI: 10.1186\/s12933-025-02767-9","DOI":"10.1186\/s12933-025-02767-9"},{"key":"ref118","doi-asserted-by":"crossref","unstructured":"Tong D, Schiattarella GG, Jiang N, et al. NAD+ repletion reverses heart failure with preserved ejection fraction. Circ Res 2021;128:1629\u201341. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.317046; PMID: 33882692. DOI: 10.1161\/CIRCRESAHA.120.317046","DOI":"10.1161\/CIRCRESAHA.120.317046"},{"key":"ref119","doi-asserted-by":"crossref","unstructured":"M\u00fcller M, Schubert T, Welke C, et al. Nitro-oleic acid enhances mitochondrial metabolism and ameliorates heart failure with preserved ejection fraction in mice. Nat Commun 2025;16:3933. https:\/\/doi.org\/10.1038\/s41467-025-59192-5; PMID: 40287424. DOI: 10.1038\/s41467-025-59192-5","DOI":"10.1038\/s41467-025-59192-5"},{"key":"ref120","doi-asserted-by":"crossref","unstructured":"Akar FG, Young LH. NAD repletion therapy: a silver bullet for HFpEF? Circ Res 2021;128:1642\u20135. https:\/\/doi.org\/10.1161\/circresaha.121.319308; PMID: 34043421. DOI: 10.1161\/CIRCRESAHA.121.319308","DOI":"10.1161\/CIRCRESAHA.121.319308"},{"key":"ref121","doi-asserted-by":"crossref","unstructured":"Bernardo BC, Ooi JYY, Weeks KL, et al. Understanding key mechanisms of exercise-induced cardiac protection to mitigate disease: current knowledge and emerging concepts; Physiol Rev 2018;98:419\u201375. https:\/\/doi.org\/10.1152\/physrev.00043.2016; PMID: 29351515. DOI: 10.1152\/physrev.00043.2016","DOI":"10.1152\/physrev.00043.2016"},{"key":"ref122","doi-asserted-by":"crossref","unstructured":"Scholte NTB, van Ravensberg AE, Shakoor A, et al. A scoping review on advancements in noninvasive wearable technology for heart failure management. NPJ Digit Med 2024;7:279. https:\/\/doi.org\/10.1038\/s41746-024-01268-5; PMID: 39396094. DOI: 10.1038\/s41746-024-01268-5","DOI":"10.1038\/s41746-024-01268-5"},{"key":"ref123","doi-asserted-by":"crossref","unstructured":"Huynh K, McMullen JR, Julius TL, et al. Cardiac-specific IGF-1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction in a mouse model of diabetic cardiomyopathy. Diabetes 2010;59:1512\u201320. https:\/\/doi.org\/10.2337\/db09-1456; PMID: 20215428. DOI: 10.2337\/db09-1456","DOI":"10.2337\/db09-1456"},{"key":"ref124","doi-asserted-by":"crossref","unstructured":"Ritchie RH, Love JE, Huynh K, et al. Enhanced phosphoinositide 3-kinase(P110\u03b1) activity prevents diabetes-induced cardiomyopathy and superoxide generation in a mouse model of diabetes. Diabetologia 2012;55:3369\u201381. https:\/\/doi.org\/10.1007\/s00125-012-2720-0; PMID: 23001375. DOI: 10.1007\/s00125-012-2720-0","DOI":"10.1007\/s00125-012-2720-0"},{"key":"ref125","doi-asserted-by":"crossref","unstructured":"Murphy SP, Ibrahim NE, Januzzi JL, Jr. Heart failure with reduced ejection fraction: a review. JAMA 2020;324:488\u2013504. https:\/\/doi.org\/10.1001\/jama.2020.10262; PMID: 32749493. DOI: 10.1001\/jama.2020.10262","DOI":"10.1001\/jama.2020.10262"},{"key":"ref126","unstructured":"Ellingsen \u00d8, Halle M, Conraads V, et al. High-intensity interval training in patients with heart failure with reduced ejection fraction. Circulation 2017;135:839\u201349. https:\/\/doi.org\/10.1161\/circulationaha.116.022924; PMID: 28082387."},{"key":"ref127","doi-asserted-by":"crossref","unstructured":"Alves AJ, Ribeiro F, Goldhammer E, et al. Exercise training improves diastolic function in heart failure patients. Med Sci Sports Exerc 2012;44:776\u201385. https:\/\/doi.org\/10.1249\/MSS.0b013e31823cd16a; PMID: 22005747. DOI: 10.1249\/MSS.0b013e31823cd16a","DOI":"10.1249\/MSS.0b013e31823cd16a"},{"key":"ref128","doi-asserted-by":"crossref","unstructured":"Mudge AM, Denaro CP, Scott AC, et al. Addition of supervised exercise training to a post-hospital disease management program for patients recently hospitalized with acute heart failure: the EJECTION-HF randomized Phase 4 trial. JACC Heart Fail 2018;6:143\u201352. https:\/\/doi.org\/10.1016\/j.jchf.2017.11.016; PMID: 29413370. DOI: 10.1016\/j.jchf.2017.11.016","DOI":"10.1016\/j.jchf.2017.11.016"},{"key":"ref129","doi-asserted-by":"crossref","unstructured":"Chitroceanu AM, Huttemeister J, Sander P, et al. Moderate intensity exercise training ameliorates the heart failure with preserved ejection fraction phenotype in a preclinical model by improving cardiometabolic fitness. Eur Heart J 2024;45(Suppl 1):ehae666.3754. https:\/\/doi.org\/10.1093\/eurheartj\/ehae666.3754. DOI: 10.1093\/eurheartj\/ehae666.3754","DOI":"10.1093\/eurheartj\/ehae666.3754"}],"container-title":["Cardiac Failure Review"],"original-title":[],"link":[{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2025.62","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T18:10:31Z","timestamp":1789063831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2025.62"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":130,"URL":"https:\/\/doi.org\/10.15420\/cfr.2025.62","relation":{},"ISSN":["2057-7540","2057-7559"],"issn-type":[{"value":"2057-7540","type":"print"},{"value":"2057-7559","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"e30"}}